Weave Bio secures $20M Series A funding to enhance its AI-native regulatory platform, led by USVP.
Oct 16, 2025•5 days ago
Amount Raised
$20 Million
Round Type
series a
Investors
Serrado CapitalTmvCharacterMagnetic VenturesInnovation EndeavorsUsvp
Description
Weave Bio, a pioneer in AI-native regulatory automation management solutions, announced its $20 million Series A funding. The round was led by USVP, with several other investors participating. This funding will help expand the reach and capabilities of Weave's platform, designed for regulatory workflows in the pharmaceutical sector. With a total of $36 million raised, Weave aims to enhance quality and reduce operational costs for its clients.
Funding Insights
Based on industry dataVC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech